BPI-23314

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameBPI-23314
Drug Alias NameBPI-23314
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain and extra terminal domain protein inhibitors
TargetsBromodomain and extra terminal domain protein
Therapy Area/IndicationsMultiple MyelomaLymphoma, Non-HodgkinLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBetta Pharmaceuticals Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBetta Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsMultiple MyelomaLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A